<DOC>
	<DOC>NCT00625495</DOC>
	<brief_summary>The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).</brief_summary>
	<brief_title>Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Heartburn on 2 out of the last 7 days prior to screening or a diagnosis of GERD (with or without a diagnosis of Erosive eosphagitis). Body Mass Index within the limits specified in the protocol History of esophageal, duodenal or gastric surgery History of severe liver disease. Any other significant disease or pathology judged to be clinically significant by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>Nexium</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>Administration methods.</keyword>
</DOC>